Despite successful restoration of epicardial vessel patency with primary percutaneous coronary intervention, coronary microvascular injury occurs in a large proportion of patients with ST-segment-elevation myocardial infarction, adversely affecting clinical and functional outcome. Ticagrelor has been reported to increase plasma adenosine levels, which might have a protective effect on the microcirculation. We investigated whether ticagrelor maintenance therapy after revascularized ST-segment-elevation myocardial infarction is associated with less coronary microvascular injury compared to prasugrel maintenance therapy.
T
he recommended treatment of ST-segment-elevation myocardial infarction (STEMI) by clinical guidelines includes prompt mechanical reperfusion with primary percutaneous intervention (pPCI) and concomitant antithrombotic therapy with a P2Y 12 inhibitor plus aspirin. 1 On the basis of 2 landmark trials, ticagrelor and prasugrel are recommended over clopidogrel because of stronger and more rapid platelet inhibition and superior efficacy. 2, 3 Comparisons between ticagrelor and prasugrel are scarce and based primarily on observational data, 4, 5 with the exception of the Prague-18 randomized trial, which compared the efficacy and safety of both thienopyridines in patients undergoing pPCI for acute MI and failed to show any differences in patient outcomes at the short term. 6 Of note, these studies have focused on the antithrombotic potency of both drugs, not on other (off-target) specific pharmacological effects that might have a salutary effect on reperfused myocardium. One such off-target property is the unique ability of ticagrelor to block the equilibrative nucleoside transporter-1 receptor, increasing local extracellular adenosine levels, particularly at sites of increased adenosine formation such as ischemia and tissue injury. 7 Adenosine is a microcirculatory vasodilator; thus, ticagrelor-mediated increased plasmatic adenosine levels might reduce coronary microvascular injury (MVI) caused by reperfusion damage in revascularized STEMI, which was previously documented in experimental studies. 8 It was demonstrated that adenosine-induced coronary blood flow could be enhanced by ticagrelor 9 and resulted in improved peripheral microvascular function, which could not be observed with prasugrel or clopidogrel. 10 The high incidence of MVI and the associated important prognostic implications make this condition a key treatment target in STEMI. 11, 12 MVI may be quantified with either the index of microcirculatory resistance (IMR), a thermodilution-derived intracoronary physiology index, or late gadolinium enhancement cardiovascular magnetic resonance (CMR), which is strongly associated with mortality in revascularized STEMI. 13 We have conducted a randomized clinical trial to determine whether, after an initial loading dose with ticagrelor, ticagrelor maintenance therapy after pPCI in STEMI reduces MVI compared with maintenance therapy with prasugrel. The study also aimed to establish the effect of ticagrelor and prasugrel therapy on microvascular obstruction (MVO), intramyocardial hemorrhage (IMH), and infarct size as determined with CMR.
METHODS Study Design, Participant Selection, and Outcome Measurements
The REDUCE-MVI trial (Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor; NCT02422888) is a multicenter superiority trial with a Prospective Randomized Open Blinded End Point design. The study complies with the Declaration of Helsinki and was approved by the institutional review board (local medical ethics committee). On request, the analytical methods will be made available to other researchers for purposes of reproducing the results or replicating the procedure; the data and study materials will not be made available.
The trial was conducted in 6 centers in the Netherlands and Spain, and the study design has been published previously. 14 In brief, patients were eligible for study participation when they presented with STEMI 1 <12 hours after onset of symptoms, received a loading dose of ticagrelor (180 mg), underwent successful pPCI of the infarct-related artery with a drug-eluting stent, and had a concomitant intermediate lesion in the non-infarct-related vessel(s). The latter inclusion criterion was introduced to avoid repeat invasive procedures solely for study purposes. When all inclusion and exclusion criteria were fulfilled (Methods 1 in the online-only Data Supplement) and witnessed oral informed consent was obtained, patients were subjected to intracoronary physiology measurements during the index procedure. After the index procedure, patients were asked to confirm study participation by written informed consent. Subsequently, patients were randomized to ticagrelor or prasugrel maintenance therapy (permuted block randomization with randomly selected block
Clinical Perspective
What Is New?
• This first randomized trial comparing maintenance treatment with ticagrelor or prasugrel after primary percutaneous coronary intervention showed no differential effect on the extent of microvascular injury and infarct size at 1 month after primary percutaneous coronary intervention.
• The attributed pleotropic benefits of ticagrelor through the adenosine metabolism could not be confirmed in an ST-segment-elevation myocardial infarction population, and plasma adenosine levels were actually not increased in patients treated with ticagrelor.
What Are the Clinical Implications?
• International guidelines provide a similar recommendation level for ticagrelor and prasugrel, but randomized trials comparing the 2 treatments head-to-head are lacking.
• Both microvascular injury and infarct size are predictors of long-term clinical outcome after primary percutaneous coronary intervention and are considered important treatment targets.
• No difference was observed for ticagrelor versus prasugrel maintenance therapy in terms of microvascular injury or infarct size after percutaneous coronary intervention-treated ST-segment-elevation myocardial infarction.
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sizes, stratified according to study center). All patients received a loading dose of ticagrelor before pPCI. Patients randomized to ticagrelor continued with ticagrelor 90 mg twice daily, whereas patients randomized to prasugrel received a loading dose of 60 mg and then continued with prasugrel 10 mg once a day to mitigate increased platelet reactivity after switching from ticagrelor to prasugrel as earlier reported. 15 The primary aim was to determine whether ticagrelor maintenance therapy compared with prasugrel maintenance therapy is associated with less MVI as assessed by IMR in the infarct-related artery at the 1-month follow-up. IMR assessment was performed simultaneously with fractional flow reserve measurement at the 1-month follow-up. CMR-derived MVO and IMH in the acute phase and infarct size and left ventricular (LV) ejection fraction at 1 month were considered secondary outcome measures. As a safety objective, we compared the occurrence of bleeding complications between patients on ticagrelor and those on prasugrel maintenance therapy during the 1-month follow-up, classified by the Bleeding Academic Research Consortium criteria. 16 Major adverse clinical events were prospectively collected between the index event and the 1-month follow-up and included death, myocardial infarction, stent thrombosis, and coronary revascularization.
17,18

Intracoronary Hemodynamic Physiology Indexes
Coronary flow reserve (CFR), IMR, baseline microcirculatory resistance (BMR), and fractional flow reserve were measured with a coronary pressure/temperature wire (Certus, Abbott, St. Paul, MN). All measurements were extracted from the RadiAnalyzer Xpress, QUANTIEN console, and all traces were analyzed offline by an independent blinded expert locally with RadiView Software (Abbott). A second independent operator in our hospital checked all analyzed traces, and if there was a discordance, both operators discussed the discordance and adjusted the values as appropriate. BMR in our study was calculated by multiplying the resting distal pressure by the mean resting transit time.
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CMR Imaging
CMR imaging was performed between 2 and 7 days and 1 month after pPCI with a 1.5-T clinical scanner (Siemens Healthcare, Erlangen, Germany). The scanning protocol included cine imaging, T2-weighted imaging, and late gadolinium enhancement. LV volumes and function were calculated from the short-axis cine images. T2-weighted images were used to identify IMH. Late gadolinium enhancement images were used to calculate infarct size and to identify MVO. Infarct size is expressed in grams and percent of LV mass. A detailed description of the acquisition techniques, CMR parameters, and postprocessing is provided in Methods 2 in the online-only Data Supplement.
Ticagrelor, Adenosine, and P2Y 12 
Inhibition levels
At the index event, at day 3, and at the 1-month follow-up, blood samples were collected for measurement of levels of ticagrelor, its active metabolite AR-C124910XX, ORIGINAL RESEARCH ARTICLE and adenosine plasma concentrations (APCs). The samples were sent to specialized laboratories blinded for analysis (Bioanalytical Covance Laboratory, Indianapolis, IN; and Q&Q labs AB, Gothenburg, Sweden, respectively; measurement details are given in in the online-only Data Supplement). Furthermore, platelet aggregation was quantified from the same blood samples (VerifyNow System, Accumetrics, San Diego, CA). High platelet reactivity was defined as P2Y 12 reaction units >235, 20 and low platelet reactivity was present when P2Y 12 reaction units were <85. 21 A detailed description is provided in Methods 3 in the online-only Data Supplement.
Sample Size Calculation and Statistical Analyses
The sample size calculation is based on a superiority design with the null hypothesis that IMR at 30 days is equal in patients on ticagrelor compared with those on prasugrel maintenance therapy. A between-group difference in mean IMR of 7 in favor of ticagrelor was considered clinically relevant. We required 47 subjects in each treatment group to detect this difference with a power of 80% (2-sided testing at α=0.05), assuming an SD of 12 in both groups. We increased the sample size by 15% to account for patients being lost to follow-up, which resulted in a total sample size of 110 patients. A blinded interim analysis at 50% of inclusion was planned, and the results, including the decision of the data safety monitoring board, are described in the Methods 4 in the online-only Data Supplement. Our study was not powered for specific differences in secondary end points. To assess a difference in dichotomous or categorical variables, the χ 2 test or Fisher exact test was used. To assess the difference in continuous variables between both treatment groups, we used the independent-samples t test for normally distributed variables and the Mann-Whitney U test in case the variable was not normally distributed. To investigate the association between continuous variables, we used the Pearson correlation for pairs of normally distributed variables and the Spearman correlation in case of skewness or extreme outliers on variables. We considered a value of P<0.05 statistically significant.
RESULTS
Study Population Characteristics
In total, 56 patients were randomized to ticagrelor 90 mg twice daily and 54 patients to prasugrel 10 mg once a day ( Figure 1 ). We have provided a screening log during the inclusion period with accompanying inclusion and exclusion criteria in Figure I in the online-only Data Supplement. During the complete follow-up period, the allocated therapy was received by 51 patients in the ticagrelor group and 51 patients in the prasugrel group. A switch to triple therapy with clopidogrel occurred in 4 patients randomized to ticagrelor and in 1 patient randomized to prasugrel because of either new-onset atrial fibrillation (clopidogrel and new oral anticoagulants) or LV thrombus (clopidogrel and acenocoumarol). In the ticagrelor group, 1 patient switched to prasugrel because of dyspnea associated with ticagrelor. An equal number of patients were lost to follow-up in both groups (n=3), and IMR could not be obtained or analyzed in 2 patients in the ticagrelor group and 3 patients in the prasugrel group. Primary end point analysis could thus be performed in 99 patients (ticagrelor, n=51; prasugrel, n=48). Clinical and procedural characteristics were well balanced between the 2 treatment groups (Tables 1 and 2 ). IMR and blood sampling during the index procedure were performed at 96±36 minutes after ticagrelor loading.
IMR, BMR, and CFR Measurements
IMR during the index procedure was not lower in the ticagrelor compared with the prasugrel group (Figure 2) . After a mean follow-up of 31±7 days, the primary end point of IMR was not superior in the ticagrelor group Table 3 .
Infarct Size and CMR
Infarct size, as represented by creatine kinase, creatine kinase-MB, and troponin T peak levels, was not different between treatment groups (Table 1) . Baseline CMR was performed in 81 patients, and follow-up CMR was performed in 96 patients. At baseline, the occurrence of MVO was not statistically different between patients on ticagrelor (28%) ant those on prasugrel (41%; P=0.35), but IMH was more frequently present in patients on prasugrel (ticagrelor, 23%; prasugrel, 43%; P=0.04). Total infarct size (ticagrelor, 7.6 g; prasugrel, 9.9 g; P=0.17) and LV ejection fraction (ticagrelor, 53%; prasugrel, 52%; P=0.61) were not superior in the ticagrelor versus the prasugrel group (Table 4) . 
Adenosine and Ticagrelor Levels
APC was available for 106 patients at baseline, 77 patients at day 3, and 105 patients at the 1-month follow-up. At baseline and the 1-month follow-up, APCs were similar in patients randomized to ticagrelor or prasugrel, as shown in Figure 3 . At day 3, similar levels of APC were found in the 2 groups (ticagrelor, 47. Table I in 
Platelet Inhibition
At baseline, platelet inhibition testing was performed in 94 patients (85%) and was not superior in either treatment group (Table 5) . After 1 month of maintenance therapy, no differences in platelet inhibition and high and low platelet reactivity were observed between the 2 treatment groups.
Clinical Outcome
From randomization to follow-up, bleeding complications were more frequent in the prasugrel group compared with the ticagrelor group (29% versus 11%; P=0.02), primarily as a result of a higher number of Bleeding Academic Research Consortium 1 bleeding complications in the prasugrel group (Table II in the online-only Data Supplement). Bleeding Academic Research Consortium 2 or greater bleeding complications occurred in 2 patients (3.7%) randomized to ticagrelor and were not observed in the prasugrel group. There was no significant difference in ticagrelor levels in patients with or without the occurrence of bleeding at the 1-month follow-up (Table II in the online-only Data Supplement). However, in patients with elevated ticagrelor levels at the 1-month 
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DISCUSSION
This is the first randomized trial to compare maintenance therapy with ticagrelor and maintenance therapy with prasugrel on coronary MVI after successful pPCI in STEMI. Our main findings are as follows: First, MVI as assessed by IMR was not reduced with ticagrelor. Second, at 1 month, no differences were observed in infarct size and LV function between the 2 treatment groups. Third, plasma adenosine levels were not increased with ticagrelor during maintenance therapy. Finally, in patients randomized to prasugrel, minor bleedings and IMH were observed slightly more frequently. MVI is considered as an important treatment target in mechanically reperfused STEMI because of the high incidence and significant prognostic implications of this condition. 22 There are 3 phases after pPCI in which MVI could be attenuated to limit infarct size. The first phase directly after pPCI consists of endothelial activation or injury, inflammatory cell plugging, microvascular destruction resulting in IMH, 12 and formation of microthrombi causing MVO (no reflow). The second phase (hours-days) is dictated by infiltrating cells. The third phase (days-months) is characterized by irreversible damage of the microcirculation. Increased levels of adenosine potentially act on all of these mechanisms. 8 MVI may be assessed with noninvasive methods such as CMR and positron emission tomography or invasively with hyperemic microcirculatory resistance and IMR. 23 A major advantage of invasive MVI assessment with IMR is that it allows risk stratification and evaluation of adjunctive treatment strategies during the acute phase of STEMI. The normal value of IMR in non-infarct-related arteries is considered to be <25. 24, 25 IMR in infarctrelated arteries has been reported to be 31 (IQR, 21-49) after pPCI. 13 Strongly increased IMR values >40 in STE-MI are associated with the extent of MVO, IMH, myocardial salvage, and mortality, 13, 26, 27 and recovery of microcirculatory resistance has been described as a strong predictor of functional outcome after pPCI. 28 In the present study, we did not observe superiority of ticagrelor in the reduction of IMR at 1 month or IMR recovery at follow-up compared with prasugrel. To avoid override of endogenous adenosine by the intracoronary-infused adenosine during IMR measurement, we also included BMR. However, no difference in BMR between groups was observed. It should be noted that the distribution of observed values was very large, limiting the value of Values are mean±SD or median (interquartile range). BMR indicates baseline microcirculatory resistance; CFR, coronary flow reserve; FFR, fractional flow reserve; and IMR, index of microcirculatory resistance. 643 ORIGINAL RESEARCH ARTICLE this index. In our study, all patients received a loading dose of ticagrelor, which might have influenced the development of MVI. However, MVI was still present in 46% of our population, which is similar to studies with a prasugrel loading dose. 23 We observed a slightly lower incidence of CMR-derived IMH in ticagrelor-treated patients, reflecting MVI with extravasation of erythrocytes during the acute phase. IMH is closely related to MVO 12 and predicts both functional and clinical outcome after STEMI. Recently, it was shown that IMH is even more closely associated with adverse outcome than MVO. 29 We did not find a significant between-group difference in CMR-derived MVO, and our study was not powered for these secondary outcomes.
Previous studies that led to the design of the present trial reported the potential beneficial effects of ticagrelor on MVI that were attributed to increased plasma levels of adenosine. 8 These experimental studies in animals [30] [31] [32] were corroborated in healthy volunteers and patients with acute coronary syndrome, 7, 9, 10, 33 showing enhanced coronary blood flow and improved peripheral and coronary microvascular function. 34 In contrast, the absence of a differential effect on microvascular and macrovascular function and the inability to improve myocardial reperfusion with ticagrelor have also been reported. [35] [36] [37] In the present study, we could not detect a difference in APCs during ticagrelor or prasugrel maintenance therapy. However, it should be noted that the measurement of endogenous plasma concentration in daily clinical practice is very cumbersome because of the extremely short half-life of adenosine and rapid cellular uptake after blood sampling, despite the application of adequate stop solution and dedicated syringes, leading to a wide range in measured APCs. 38 In addition, as a result of an active endothelial adenosine metabolism, circulating adenosine does not represent myocardial interstitial adenosine concentration, and we were not able to measure local adenosine levels at the tissue level. The ongoing ISAR-REACT-5 trial (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800) is currently investigating the long-term clinical outcome in patients with acute coronary syndrome on either ticagrelor or prasugrel maintenance therapy. 39 A substudy of this trial investigated the potential effect of reticulated platelets on ADP-mediated platelet aggre- Ticagrelor levels are represented in a scatterplot for patients randomized to ticagrelor and prasugrel with specification of those patients who switched to a different therapy during follow-up. The cross denotes the median and interquartile range. There were no significant differences in the ticagrelor level during the index procedure at baseline. At the 1-month follow-up, significantly higher levels of ticagrelor were observed in the ticagrelor group.
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gation in 124 patients with acute coronary syndrome treated with ticagrelor or prasugrel. Those investigators reported that reticulated platelets (increased during acute coronary syndrome) are less inhibited by prasugrel compared with ticagrelor, resulting in increased platelet reactivity in the prasugrel group. 40 However, in our study, platelet reactivity was equal in patients with prasugrel and ticagrelor. There was a significant correlation between ticagrelor levels and platelet inhibition at the acute moment but not at the 1-month follow-up. The reason might be that a per-protocol analysis was performed in a smaller group of patients at follow-up (n=53) compared with at the acute moment.
Finally, we observed a slightly larger proportion of Bleeding Academic Research Consortium 1 minor bleedings in patients on prasugrel, which is probably not of clinical importance. 41, 42 In patients with ticagrelor maintenance therapy, elevated ticagrelor levels were associated with a mild increase in bleeding at the 1-month follow-up. The present study was not designed or powered to detect differences in clinical outcome. The randomized Prague-18 trial 6 and a metaanalysis did not show a difference in clinical outcome and major bleeding complications between ticagrelor and prasugrel. 4 Future randomized trials with sufficient power will establish the difference in long-term clinical outcome between prasugrel and ticagrelor maintenance therapy in STEMI.
Limitations
Before pPCI, all patients were loaded with ticagrelor because this is standard care in the participating centers, which might have modified MVI at the index event. The sample size calculation was based on a study among patients with stable coronary artery disease 43 because at the time of protocol drafting no data were available on IMR values 1 month after pPCI in STEMI. It should be emphasized that the observed SD is larger than what we initially expected (SD 12), leading to a decreased power. With the increased variability, 128 additional patients would need to be included to achieve a power of 80%. However, given that the observed effect was in the opposite direction than hypothesized, it is unlikely that adding 99 extra patients to our study would yield a significant improvement of IMR in the ticagrelor group. The relatively low rates of classic risk factors, small infarct size and preserved ejection, could have influenced IMR values as well as the potential effects of the pharmacological intervention. We have used late gadolinium enhancement to detect MVO, which is less sensitive compared with first-pass perfusion imaging or early gadolinium enhancement. However, it has the highest prognostic value. 44 The administration of adenosine intravenously during IMR measurements could theoretically influence MVI. However the values observed in our cohort are comparable to values from other STEMI cohorts as recently published. 45 In addition, the natural recovery of microvascular dysfunction over time might have diluted the positive effects of ticagrelor, despite the fact that microcirculatory resistance is still hampered in 50% of patients at 1 month. 46 Finally, we included just a fraction of all screened patients with STEMI because of the rather complex study design of our proof-of-principle study, and thus, it is not possible to extrapolate our results to all patients with STEMI.
Conclusions
In patients with STEMI, ticagrelor maintenance therapy was not superior to prasugrel in preventing MVI as assessed with IMR at the 1-month follow-up, and this resulted in a comparable infarct size at 1 month. Values are median (interquartile range), mean±SD, or number (percent). P2Y 12 platelet inhibition was determined during the index procedure (baseline) and the 1-month follow-up. HPR indicates high platelet reactivity; LPR, low platelet reactivity; and PRU, platelet reactivity unit.
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